Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 29 April, 2008

Summit Corporation PLC

Research Update - New Positive Data from DMD Pr...

Summit Corporation plc
("Summit plc" or "the Company")
*��� Drug candidate SMT C1100 boosts muscle strength and function in
  preclinical studies
*��� Third independent verification of Summit's therapeutic approach
Oxford, UK, 29 April 2008 - Summit Corporation plc (AIM: SUMM), a
leading UK biotechnology company, today reports positive data from
the Company's preclinical development programme targeting the fatal
genetic disease, Duchenne muscular dystrophy (DMD).
In a series of tests using the 'gold standard' preclinical in-vivo
model of DMD, SMT C1100 was shown to increase significantly the
strength of muscles when compared to no treatment. �A synergistic
benefit in reducing muscle fatigue during exercise (ability to walk
longer distances) was seen with SMT C1100 and steroid treatment
(prednisolone).� Steroids are currently the only frontline therapy
for DMD.
Importantly, this study, which�demonstrates a reduction in muscle
fatigue during exercise, is a surrogate for the agreed primary
clinical endpoint in human clinical trials. It is designed to
demonstrate that patients' muscle function is improved by measuring
the increase in distance they can walk.
These latest data were presented to leading research scientists and
companies in the field of neuromuscular diseases at the New
Directions in Muscle Biology and Diseases conference, held in New
Orleans, USA (27-30 April). �A copy of the presentation is available
on request from [email protected]
The studies' were undertaken at the University of Bari, Italy, by
Professor Annamaria De Luca, a leading expert in neuromuscular
diseases, and is the third independent verification of the potential
of Summit's unique therapeutic approach to treating DMD.� Summit's
plan is to conclude preclinical development work by the end of 2008
and begin Phase I clinical trials shortly afterwards.
Commenting on the results, Professor Kate Bushby, a leading clinician
and researcher in neuromuscular diseases at Newcastle University,
said: "These are very encouraging results, which, if they can be
replicated in patients, will provide real optimism that an effective
long-term treatment for DMD can be developed."
Richard Storer, DPhil, Chief Scientific Officer of Summit commented:
"We are very pleased with how our DMD programme is progressing.� In
preclinical studies to date, SMT C1100 has shown positive results
consistently that give us great confidence that we will soon be able
to progress this novel candidate into patients. If it is successful
in the clinic, this will be a first in class drug offering
considerable hope to all DMD patients. Furthermore, it will offer
potential partners a significant commercial advantage in this area of
high unmet medical need and strengthens our portfolio of exciting
drug programmes targeting acne, Parkinson's disease and oncology, all
of which represent attractive licensing opportunities."
About DMD and Summit's Therapeutic Approach
DMD is a fatal neuromuscular disease that only affects young males.
Owing to an inherited genetic defect, DMD patients lack an important
protein called dystrophin, which is crucial to maintaining muscle
integrity. The absence of dystrophin results in extensive muscle
wasting that severely restricts the mobility of DMD patients by their
teen years and is ultimately fatal in their twenties.� There is no
cure for the disease and steroid treatment, the only frontline
therapy, acts to only delay the patients' requirement of a
Summit has identified SMT C1100, a proprietary small molecule that
acts to replace the missing dystrophin by increasing levels of a
functionally similar protein called utrophin. Summit believes the
major advantages of this approach is that it is an oral drug and has
the potential to be effective in the treatment of all DMD patients,
whereas other current treatments in development are expected to be
limited to specific groups of patients.
                             -- ENDS --
For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Darren Millington, ACMA, Chief Financial Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Sylvie Berrebi
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a leading UK biotechnology company that discovers and
develops proprietary new drugs. The Company's internal drug
development programmes are underpinned by its advanced carbohydrate
chemistry and zebrafish drug screening technology platforms, which it
also provides on a collaborative or fee-for-service basis to the
pharmaceutical industry.
Summit plc has a broad range of drug discovery programmes in the
clinical, pre-clinical and discovery stages of development, which
target serious diseases with a high unmet medical need. These
therapeutic areas include neurological disorders, anti-infectives,
ophthalmic diseases and oncology.
Summit plc's in-house drug development capabilities combine
world-class expertise in both carbohydrate chemistry with
high-volume, high-content screening using its proprietary zebrafish
technologies. These whole organism screens have the potential to
dramatically decrease the time and cost of drug discovery and
development by delivering data that are highly predictive of the
efficacy and toxicity of potential drug compounds in humans.
The company listed on the AIM market of the London Stock Exchange in
October 2004 - symbol: SUMM� Further information about the company is
available at



a d v e r t i s e m e n t